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Tyramine, formed by the decarboxylation of tyrosine, is a natural constituent of numerous food 
products. As an indirect sympathomimetic, it can have potentially dangerous hypertensive 
effects. In vitro data indicated that the pharmacokinetics of tyramine possibly depend on the 
organic cation transporter OCT1 genotype and on the CYP2D6 genotype. Since tyramine is 
a prototypic substrate of monoamine oxidase A (MAO-A), genetic polymorphisms in MAO-A 
may also be relevant. The aims of this study were to identify to what extent the interindividual 
variation in pharmacokinetics and pharmacodynamics of tyramine is determined by genetic 
polymorphisms in OCT1, CYP2D6, and MAO-A. Beyond that, we wanted to evaluate tyramine 
as probe drug for the in vivo activity of MAO-A and OCT1. Therefore, the pharmacokinetics, 
pharmacodynamics, and pharmacogenetics of tyramine were studied in 88 healthy volunteers 
after oral administration of a 400 mg dose. We observed a strong interindividual variation in 
systemic tyramine exposure, with a mean AUC of 3.74 min*µg/ml and a high mean CL/F 
ratio of 107 l/min. On average, as much as 76.8% of the dose was recovered in urine in 
form of the MAO-catalysed metabolite 4-hydroxyphenylacetic acid (4-HPAA), confirming 
that oxidative deamination by MAO-A is the quantitatively most relevant metabolic pathway. 
Systemic exposure of 4-HPAA varied only up to 3-fold, indicating no strong heritable variation 
in peripheral MAO-A activity. Systolic blood pressure increased by more than 10 mmHg 
in 71% of the volunteers and correlated strongly with systemic tyramine concentration. In 
less than 10% of participants, individually variable blood pressure peaks by >40 mmHg 
above baseline were observed at tyramine concentrations of >60 µg/l. Unexpectedly, the 
functionally relevant polymorphisms in OCT1 and CYP2D6, including the CYP2D6 poor and 
ultra-rapid metaboliser genotypes, did not significantly affect tyramine pharmacokinetics or 
pharmacodynamics. Also, the MOA-A genotypes, which had been associated in several 
earlier studies with neuropsychiatric phenotypes, had no significant effects on tyramine 
pharmacokinetics or its metabolism to 4-HPAA. Thus, variation in tyramine pharmacokinetics 
and pharmacodynamics is not explained by obvious genomic variation, and human 
tyramine metabolism did not indicate the existence of ultra-low or -high MAO-A activity.
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inTrODUCTiOn
The biogenic amine tyramine is formed through decarboxylation 
of tyrosine by microbes, and is thus found in numerous fermented, 
aged, or ripened protein-rich food products (McCabe-Sellers et al., 
2006; Ladero et al., 2010; Gillman, 2018). Tyramine functions as an 
indirect sympathomimetic by promoting the release of noradrenaline 
from synaptic vesicles, thereby having hypertensive effects (referred 
to as the tyramine pressor response; Gillman, 2018). In combination 
with monoamine oxidase (MAO) inhibitors, tyramine can cause a 
so-called hypertensive crisis that, beside symptoms like headache, 
migraine, nausea, or vomiting, may even cause end-organ damage, 
intracerebral haemorrhage, and death (Blackwell, 1963; Gillman, 
2018; Salter and Kenney, 2018). Nowadays, potential new drugs 
known or suspected to inhibit MAO are usually assessed for 
potential interactions with oral tyramine in clinical studies.
Genomic variation in tyramine pharmacokinetics and 
pharmacodynamics has thus far only been scarcely studied. 
MAOs catalyse the oxidative deamination of tyramine to 
4-hydroxyphenylacetaldehyde, which is then converted to 
4-hydroxyphenylacetic acid (4-HPAA; Figure 1). Tyramine was the 
first known substrate for MAO, which had initially been referred to 
as tyramine oxidase (Hare, 1928), and may still today be a suitable 
in vivo probe drug for studying MAO activity. Although tyramine 
is a substrate of both MAO-A and MAO-B, the tyramine pressor 
response occurs only with MAO-A inhibition (Finberg and Tenne, 
1982; Finberg, 2014). MAO-A in the intestinal mucosa is likely to be 
responsible for the low oral bioavailability of tyramine, and systemic 
tyramine is eliminated via hepatic MAO (Gillman, 2018). Literature 
data on the impact of genetic variation on MAO-A activity is scarce, 
but a few polymorphisms were described to modulate expression and 
catalytic activity (Hotamisligil and Breakefield, 1991; Jansson et al., 
2005; Zhang et al., 2010). In particular, a MAO-A promoter variable 
number tandem repeat (VNTR) has been studied experimentally 
and in clinical association studies (Sabol et al., 1998; Deckert et al., 
1999; Liu et al., 2013). However, the correlation between MAO-A 
genotype and phenotype is not fully clear (Cirulli and Goldstein, 
2007), and, to the best of our knowledge, the relation with tyramine 
pharmacokinetics has not yet been studied in humans.
Systemic tyramine concentrations could also be influenced 
by other enzymes, such as CYP2D6. The genetically highly 
polymorphic CYP2D6 converts tyramine to dopamine (Hiroi et al., 
1998; Bromek et al., 2011), and it was proposed that CYP2D6 could 
be involved in the hepatic elimination of tyramine (Niwa et al., 2011). 
However, it has not yet been studied in humans whether tyramine 
pharmacokinetics depend on the CYP2D6 genotype.
At physiological pH, 99.9% of tyramine is protonated 
and is thus unable to readily enter cells by passive diffusion. 
Earlier studies have reproducibly demonstrated that tyramine 
is a substrate of the organic cation transporter 1 (OCT1, or 
SLC22A1), and that frequent naturally occurring variants in 
OCT1 have reduced or absent activity in cellular uptake of 
tyramine (Breidert et al., 1998; Seitz et al., 2015). Thus, for hepatic 
clearance of systemically available tyramine in humans, OCT1 
might play a relevant role, with reduced clearance in carriers of 
decreased or zero function OCT1 alleles. The OCT1 genotype 
could therefore be another possible factor that determines an 
individual’s response to tyramine.
Tyramine pharmacogenetics may also be of general 
biological interest, since the protection from potentially toxic 
substances could have been a driving force for the evolution of 
genetically polymorphic drug membrane transporters and drug 
metabolising enzymes.
The aim of the present study was to elucidate the genetic factors 
that determine systemic tyramine exposure and tyramine blood 
pressure effects. To this end, the pharmacokinetics of tyramine 
were studied in 88 healthy volunteers after oral administration 
of 400 mg of tyramine. Furthermore, the impact of MAO-A, 
CYP2D6, and OCT1 genotypes on the pharmacokinetics of 
tyramine and its main metabolite 4-HPAA as well as on tyramine 
blood pressure effects was analysed.
MATeriALS AnD MeTHODS
Subjects and Study Design
In this open-label pharmacokinetic/pharmacodynamic study, 
pharmacokinetics and effects of 400 mg oral tyramine were analysed 
in relation to MAO-A, CYP2D6, and OCT1 genotypes in 88 healthy 
volunteers. Eighty percent of the participants were unselected 
volunteers from Göttingen area in Germany; the remaining 20% 
were selected from an internal database to enrich the study sample 
with rare OCT1 or CYP2D6 variants. With widely accepted 
statistical criteria (type I error of 0.05 and type II error of 0.2), at least 
FigUre 1 | Selected pathways of tyramine formation and metabolism. Prior to 
oxidative deamination by MAO-A, tyramine has to traverse the cell membrane, 
most likely supported by organic cation transporters such as OCT1.
Abbreviations: 4-HPAA, 4-hydroxyphenylacetic acid; MAO, monoamine oxidase; 
OCT, organic cation transporter; VNTR, variable number tandem repeat.
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10 subjects with genetically defined very low activity of OCT1 or 
CYP2D6 and a similar or higher number without deficiency should 
be sufficient to confirm a relevant 50% change in tyramine plasma 
AUC as a result of genetic variation. Because of the very diverse and 
not pharmacokinetic-based literature data on the functional effects of 
MAO-A polymorphisms, no power calculation could be performed 
with regard to MAO-A genotypes. However, a sample size of nearly 
a hundred individuals should be sufficient to find genotypes with a 
population frequency of at least 5%. All volunteers gave their written 
informed consent before participation in the study. The study was 
approved by the ethics committee of the University of Göttingen. It 
was registered at the German Clinical Trials Registry and the World 
Health Organization International Clinical Trials Registry Platform 
(DRKS00008915; https://www.drks.de/DRKS00008915).
Healthy male and female volunteers aged between 18 and 
50 years with a body mass between 50 and 100 kg and a body 
mass index of 18–30 were eligible for inclusion. Volunteers with 
known intolerance to tyramine or those who required regular 
drug treatments other than oral contraceptives were not included. 
Further reasons for exclusion were any chronic illnesses that 
significantly raise the risk for cardiovascular events. All subjects 
were healthy according to a detailed medical history, medical 
examination, electrocardiogram, urine status and clinical 
chemistry, and haematology parameters (sodium, potassium, total 
bilirubin, aspartate aminotransferase, alanine-aminotransferase, 
creatinine, C-reactive protein, thyroid stimulating hormone, 
haemoglobin, erythrocyte, thrombocyte, and leucocyte counts).
Tyramine (99% purity; Sigma-Aldrich, Darmstadt, Germany) 
was recrystallised from double-distilled water and stored at room 
temperature. Purity was confirmed by HPLC. Gelatine capsules 
containing 400 mg of tyramine were prepared and stored at room 
temperature. To avoid interference by dietary tyramine, food and 
drink (including alcohol) consumption was prohibited from the 
evening before the study day until the last blood and urine sampling, 
except for water at any time and bread with butter 3 h before and 
3 h after tyramine administration. A medical examination and 
electrocardiogram measurement were conducted 3 h prior to 
tyramine administration. Blood samples were drawn 3 h before and 
at the following times after tyramine intake: 15, 30, and 45 min as 
well as 1, 1.5, 2, 2.5, 3, 4, and 6 h. Urine samples were taken from 3 
h to 10 min before tyramine administration as well as from 0 to 3 
h and from 3 to 6 h after. Blood samples were centrifuged (10 min, 
4°C, 4,000 rpm) and plasma and urine samples were stored at −20°C 
until analysis. Blood pressure and heart rate were measured 3 h, 35 
min, and 10 min before tyramine administration, and subsequently 
in 15 min intervals until 6 h after. In a subgroup of eight participants, 
blood pressure was continuously monitored based on an analysis 
of pulse pressure curves using the SOMNOtouch™ NIPB non-
invase system (SOMNOmedics GmbH, Randersacker, Germany). 
An orthostatic blood pressure test was performed 10 min before 
as well as 30 min and 1.5 h after tyramine intake. Pupillometry 
was performed 35 min prior to, and 1, 2, and 6 h after tyramine 
administration. Participants were asked to report on symptoms 
possibly related to tyramine (headache, fatigue, sleepiness, visual 
or hearing impairments, restlessness, nausea, dizziness, dry mouth, 
tremor, sensation of cold, and heart palpitation) using visual 
analogue scales 3 h before and 1, 3, and 6 h after tyramine intake.
Bioanalytics
Plasma and urine concentrations of tyramine and 4-HPAA 
were analysed by HPLC with tandem mass spectrometry using 
tyramine-d4 (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) 
as internal standard. GR 49336 (5-[[(methylamino)sulfonyl]
methyl]-1H-indole-3-acetic acid; Santa Cruz Biotechnology, 
Inc.) was used as internal standard for 4-HPAA. The analytical 
standards for tyramine were obtained from Fluka (Morristown, 
NJ, USA) and for 4-HPAA from Sigma-Aldrich (Darmstadt, 
Germany). The limit of detection for tyramine was 0.1 ng/ml in 
plasma and 10 ng/ml in urine; for 4-HPAA, it was 5 ng/ml in 
plasma and 0.5 µg/ml in urine. The limit of quantification for 
tyramine was 0.25 ng/ml in plasma and 15 ng/ml in urine; for 
4-HPAA, it was 15 ng/ml in plasma and 1.5 µg/ml in urine. Plasma 
and urine concentrations of dopamine and N-methyltyramine 
were found to be below the limit of detection of 1 ng/ml.
200 µl of plasma were precipitated in 1.5 ml Eppendorf tubes 
with 400 µl acetonitrile/methanol (9:1, v:v), including the internal 
standards. After 10 min on ice, tubes were centrifuged for 30 min 
at 13,000 rpm, and 300 µl of the supernatant were transferred to a 
microtiter plate. The supernatant was evaporated using nitrogen and 
re-dissolved in 0.1% formic acid. 10 µl were injected into the HPLC 
system. Chromatography was performed using a Shimadzu Nexera 
system with an API 4000 detector. Separation for analysis of tyramine 
and methyltyramine was performed at 40°C on a Brownlee SPP 
RP-Amide 100 x 4.6 mm, 2.7 µm particle size, column using water 
with 0.1% (v/v) formic acid, 2.57% acetonitrile, and 0.43% methanol 
as eluent. Detection (positive mode) of tyramine was based on the 
masses 139.1/121.1 and for tyramine-d4 on 142.0/125.0. Calibration 
range was 0.5 to 200 µg/l with coefficients of variation of 4.6%, 2.8%, 
and 2.6% at 2, 20, and 150 µg/l, respectively. Analysis of 4-HPAA 
was performed on the same system, using 0.1% formic acid, 17.14% 
acetonitrile, and 2.86% methanol as eluent and detection in the 
negative mode based on the masses 151.0/107.2 for 4-HPAA and 
281.2/142.1 for the internal standard. Calibration range was between 
0.03 and 20 mg/l and coefficients of variation were 4.7%, 4.2%, and 
3.7% at 1, 5, and 15 mg/l.
genotyping
Genomic DNA was isolated from venous blood samples via 
automated solid phase extraction (EZ1 DNA Blood kit; Qiagen, 
Hilden, Germany). Genotyping was performed using single-
base primer extension, as described previously (Seitz et al., 
2015). The following genetic polymorphisms were analysed for 
MAO-A: rs2064070, rs6323, rs1137070, rs909525, rs2072743, 
rs1800464, rs1799835, and the 30-bp-VNTR in the proximal 
promoter region (Sabol et al., 1998); for CYP2D6: *2, *3, *4, 
*5, *6, *9, *10, *35, *41, and gene duplication; for OCT1: S14F 
(rs34447885), S189L (rs34104736), R61C (rs12208357), Q97K 
(c.289C > A), P117L (rs200684404), R206C (c.616C > T), G401S 
(rs34130495), M420del (rs72552763), G465R (rs34059508), 
C88R (rs55918055), and G220V (rs36103319).
Statistics
The primary endpoint was the AUC of tyramine in plasma. 
Secondary endpoints were the other pharmacokinetic 
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parameters of tyramine and its metabolite 4-HPAA, as 
well as heart rate, blood pressure, pupil size effects, and 
possible adverse events (headache, fatigue, visual or hearing 
impairments, restlessness, nausea, dizziness, dry mouth, 
tremor, hypothermia, heart palpitations). In addition, the 
cumulative amounts of tyramine and 4-HPAA excreted in 
urine were measured over time periods of 3 h before (baseline) 
and 6 h after application.
Pharmacokinetic parameters were calculated by non-
compartmental analysis using Phoenix 64 WinNonlin version 6 
(Certara USA, Inc., Princeton NJ, USA). AUCinf of tyramine was 
calculated from time of dosing using the linear/log trapezoidal 
rule, and extrapolated to inﬁnity based on the last predicted 
concentration and using the terminal elimination rate constant 
(lambda z). Further parameters included the total plasma 
clearance after oral administration (CL/F) and the terminal half-
life (t1/2), which were calculated as CL/F = dose/AUCinf and t1/2 = 
ln(2)/lambda z.
The correlation between tyramine plasma AUC (primary 
endpoint) and MAO-A, CYP2D6, and OCT1 genotype was 
calculated via multiple regression analysis. The genotypes were 
categorised into 0, 1, or 2 active alleles for OCT1 and into 0, 0.5, 
1, 1.5, 2, or >2 active alleles for CYP2D6, depending on their 
known effects on transporter/enzyme activity.
reSULTS
In total, 88 healthy volunteers (54 female, 34 male) participated 
in the study. The subjects were between 18 and 49 years of 
age (Table  1). The participants were genotyped for various 
well-known and common MAO-A, CYP2D6, and OCT1 
polymorphisms (further data in Supplementary Table 1). All 
participants received 400 mg tyramine orally. There were no 
serious adverse events caused by tyramine.
Pharmacokinetics of Tyramine and 4-HPAA
Baseline plasma concentrations of tyramine were below the 
limit of quantification in 98% of participants; in the remaining 
two subjects, the mean (individual values) concentration 
was 0.39 (0.25 & 0.53) ng/ml. The corresponding baseline 
plasma 4-HPAA concentrations were less than the limit of 
quantification in 84%, and mean (range) concentration in the 
remaining subjects was 70 (31–201) ng/ml. Baseline tyramine 
recovery in the urine cumulated for 3 h prior to tyramine 
administration was lower than the limit of quantification in 
2% of participants; for the remaining volunteers, the mean 
(range) was 0.055 (0.007–0.222) mg. The baseline urinary 
recovery of 4-HPAA was below the limit of quantification in 
26%, and mean (range) in the remaining subjects was 2.65 
(0.67–9.05) mg.
Following tyramine administration, increases in the 
plasma concentrations of tyramine and the metabolite 
4-HPAA were seen in all participants. The mean plasma 
4-HPAA concentrations were at any time point 14- to 4,600-
fold higher than those for tyramine (Figure 2). In spite of 
highly standardised conditions for dosing and intake, tmax of 
tyramine was very diverse, ranging between 13 and 120 min. 
A large variation in tmax was also observed for 4-HPAA, which 
ranged from 29 to 150 min (Table 2). Tyramine and 4-HPAA 
tmax correlated strongly (p < 0.001). The AUCs (primary 
endpoint) and the amounts excreted during the first 6 h 
following tyramine administration (Ae0-6h) varied strongly for 
tyramine but were more uniform for 4-HPAA (Figure 3). In 
the 0–6 h urine fractions, the median of the dose recovered as 
the sum of tyramine and 4-HPAA was 72.2%, of which 99.8% 
was in the form of the metabolite. Given the high clearance 
to bioavailability ratio of 107 l/min, the bioavailability of 
tyramine is, as known, very low. It is most likely less than 
1% when assuming that the total systemic clearance is not 
higher than 1 l/min. The higher plasma concentrations of 
4-HPAA and the relatively high urinary recovery in form of the 
metabolite indicates that tyramine is most likely absorbed at 
the intestinal mucosa and directly metabolised there by MAO-
A, or immediately afterwards in the liver, before reaching the 
systemic circulation. This intensive first-pass effect is, however, 
apparently not sufficient to prevent a significant increase in 
blood pressure in some of the study participants.
We observed no statistically significant dependence of 
tyramine AUC on age, weight, height, body mass index, sex, 
smoking status, consumption of alcohol, or the use of oral 
contraceptives, but tyramine Ae0-6h varied significantly by sex 
(male 9.69 µmol, female 7.07 µmol; p = 0.002, Mann-Whitney 
U test). A negative correlation was seen for 4-HPAA AUC with 
body height (p < 0.001, two-tailed) and body weight (p < 0.001, 
two-tailed, Figure 4). Furthermore, 4-HPAA plasma AUC was 
lower in male compared to the female participants (p = 0.005, 
two-tailed t-test; Figures 4 and 5).
TABLe 1 | Characteristics of the study population (n = 88).
Mean Median SD Minimum Maximum
Age 27.0 25 6.7 18 49
Body height (cm) 174.0 174.5 8.8 157 199
Body mass (kg) 69.9 68.7 11.2 49.0 99.7
Body mass index 23.0 22.7 2.77 18.4 29.8
n (%)
Sex 34 (39%) male
Smoking habit 21 (24%) smokers
Alcohol drinking habit 82 (93%) consumers
Oral contraceptive use (females only) 27 (50%) yes
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Pharmacogenetics of Tyramine and 4-HPAA
The participants were genotyped for the polymorphisms in 
the MAO-A, CYP2D6, and OCT1 genes that are presumed or 
known to be relevant in European populations. These include 
for MAO-A: rs2064070, rs6323, rs1137070, rs909525, rs2072743, 
rs1800464, rs1799835, and the 30-bp-VNTR in the proximal 
promoter region (Sabol et al., 1998). Since MAOA is found on 
the X-chromosome, males and females were analysed separately. 
None of the MAO-A polymorphisms presumed, according to the 
literature, to influence expression levels or result in amino acid 
exchange had any significant impact on tyramine or 4-HPAA 
pharmacokinetics, analysed as plasma AUCinf (the pre-defined 
primary endpoint), Ae0-6h, and metabolic ratio calculated as 
the ratio of the AUCs of tyramine and 4-HPAA (Figure 5, 
Supplementary Figure 1, Supplementary Table 1).
All frequent CYP2D6 variants typically relevant in European 
populations (the alleles *2, *3, *4, *5, *6, *9, *10, *35, *41, and 
gene duplication) were analysed, but there was not any relation 
between tyramine or 4-HPAA pharmacokinetic parameters 
and the CYP2D6 genotype-based activity scores (Figure 5). 
Dopamine could nevertheless be formed from tyramine by 
CYP2D6 but only to a very minor extent. We therefore looked 
at physiological parameters potentially indicating CYP2D6-
dependent dopamine formation, such as systolic and diastolic 
blood pressure or effects of dopamine in the central nervous 
system, including pupillometry. However, none of the parameters 
differed between the groups defined by the CYP2D6 genotype.
We hypothesised at the beginning of this study that the 
genetically highly polymorphic OCT1 could be involved in hepatic 
uptake of tyramine from the blood circulation, as tyramine is a 
substrate with nanomolar affinity (Breidert et al., 1998). Thus, 12 
homozygous or compound heterozygous carriers of OCT1 alleles 
that are known to confer very low to absent tyramine transport 
activity in vitro were included (Seitz et al., 2015). Altogether, 
the following variants were investigated: S14F (rs34447885), 
S189L (rs34104736), R61C (rs12208357), Q97K (c.289C > A), 
P117L (rs200684404), R206C (c.616C > T), G401S (rs34130495), 
M420del (rs72552763), G465R (rs34059508), C88R (rs55918055), 
and G220V (rs36103319). However, neither the pharmacokinetic 
parameters (Figure 5) nor the blood pressure response or other 
parameters varied among the OCT1 genotypes. Furthermore, 
analyses differentiating between the specific OCT1 alleles did not 
show statistically significant differences (Supplementary Table 1).
effects on Blood Pressure and Heart rate
Following tyramine administration, systolic blood pressure 
increased by more than 10 mmHg in 71% of the volunteers. 
Concentration-effect analyses showed a rise in systolic blood 
pressure at tyramine plasma concentrations of approx. 60 µg/l 
and above (Figure 6). The diastolic blood pressure increased at 
concentrations higher than 100 µg/l (Supplementary Figure 2). 
As with the systemic tyramine exposure, strong interindividual 
variations were seen in blood pressure response, and for the 
systolic blood pressure in particular (reaching increases in 
systolic blood pressure by up to 103 mmHg above baseline 
values measured on the same day; Figure 7). As illustrated, the 
maximum rise in systolic blood pressure correlated strongly with 
the maximum systemic tyramine concentrations.
TABLe 2 | Pharmacokinetic parameters of tyramine and 4-HPAA.
Tyramine 4-HPAA
AUCinf (min*µg/ml) 3.74 (1.31–10.7) 1298 (1249–1350)
t1/2 (min) 55 (25–124) 73 (71–75)
tmax (min) 46 (13–120) 88 (29–150)
Cmax (µg/ml) 0.087 (0.019–0.398) 9.04 (8.66–9.44)
CL/F (l/min) 107 (38–305)
CLrenal (l/min) 0.26 (0.11–0.61) 0.24 (0.09–0.60)
Ae0-6h (mg) 0.98 (0.34–2.77) 307 (130–729)
2x Ae-3-0h (mg) 0.089 (0.025–0.316) 4.32 (1.26–14.84)
Data is given as geometric mean with the geometric 95% confidence interval 
in parentheses, except for tmax, for which the median and the range is given; 
n = 88. Baseline amount excreted (Ae-3-0h) data were multiplied by 2 for better 
comparison to the 6 h post-application measurement interval.
FigUre 2 | Plasma concentrations of tyramine (blue circles) and 4-HPAA (green squares) over time, shown (A) for each participant and (B) as means + SD (n = 88).
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FigUre 3 | Frequency distribution of plasma AUCs for (A) tyramine and (B) 4-HPAA, as well as (C) tyramine Ae0-6h, (D) 4-HPAA Ae0-6h, (e) tyramine Ae-3-0h, and 
(F) 4-HPAA Ae-3-0h. Baseline Ae (Ae-3-0h) data were multiplied by 2 for better comparison to the 6h post-application measurement interval.
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Beside conventional sphygmomanometric blood pressure 
measurements at 15-min intervals, blood pressure was measured 
via the pulse transit time at every heart beat. It showed that the 
blood pressure peaks triggered by tyramine can be very strong but 
were usually short-lived. This is illustrated by the blood pressure 
reactions of three participants in Figure 6. They are not, however, 
representative for all volunteers, as the observed blood pressure 
effects varied greatly not only with respect to the intensity but 
FigUre 5 | Distribution of tyramine plasma AUCs based on the genotypes of (A) CYP2D6, (B) OCT1, and (C) MAO-A VNTR. (D) Distribution of 4-HPAA plasma 
AUCs in relation to the MAO-A VNTR genotype.
FigUre 4 | Dependence of the tyramine metabolite 4-HPAA on (A) sex (p = 0.001), (B) body height (p < 0.001; two-tailed), and (C) body weight (p < 0.001; two-tailed).
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FigUre 6 | (A) Time course of systolic blood pressure shown for each participant. (B) Systolic blood pressure relative to plasma tyramine concentration, shown 
as individual readings. More information and similar representations for diastolic blood pressure and heart rate are shown in Supplementary Figure 2.  
(C) Correlation between maximum systemic tyramine concentration and maximum rise in systolic blood pressure (p < 0.001, two-tailed). (D–F) Individual 
exemplary time courses of blood pressure and heart rate, measured at very short intervals via the pulse transit time. For reference, the plasma concentrations of 
tyramine have been superimposed.
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also in the time of onset. For instance, in one participant (Figure 
6), the blood pressure reaction occurred much delayed at 90 min 
after tyramine administration.
The interindividual variation could not be linked to the 
individual’s MAO-A, CYP2D6, or OCT1 genotypes; no difference 
in the maximum increases in systolic blood pressure, diastolic 
blood pressure, and heart rate was found for the polymorphisms 
investigated here (data not shown).
Adverse Symptoms
Possible adverse symptoms of tyramine were assessed by visual 
analogue scales. Positive correlations (two-tailed; Figure 8) were 
seen for systemic tyramine concentration with heart palpitation 
(p < 0.001) and inner restlessness (p = 0.02). Systemic 4-HPAA 
concentration also correlated (two-tailed; Figure 8) positively 
with heart palpitation (p < 0.001) as well as with headache 
(p  = 0.01), dizziness (p = 0.03), and weakly with dry mouth 
(p = 0.049). Repeated pupillometric analyses to detect possible 
central adrenergic effects by tyramine showed no difference in 
pupil size and the pupil reaction to light before and after tyramine 
administration (data not shown).
DiSCUSSiOn
To summarise, our results indicate that OCT1 and CYP2D6 
are of little or no importance for tyramine pharmacokinetics. 
In contrast, the study confirmed the relevance of MAO-A, 
but indicated that functionally relevant genomic variation in 
MAO-A is apparently not frequent. Clearly, our data show that 
pharmacokinetics of tyramine varies greatly between individuals. 
However, the genetic polymorphisms that account for this 
variation still remain elusive.
FigUre 7 | Frequency distribution of the maximum increases in (A) systolic blood pressure and (B) the time till this was reached, as well as of the maximum 
increases in (C) diastolic blood pressure and (D) heart rate.
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FigUre 8 | Adverse symptoms assessed by visual analogue scales in correlation (two-tailed) to systemic tyramine and 4-HPAA concentrations. (A) Heart palpitation 
(p < 0.001) and (B) Inner restlessness (p = 0.02) in correlation to tyramine. (C) Heart palpitation (p < 0.001), (D) headache (p = 0.01), (e) dizziness (p = 0.03), and 
(F) dry mouth (p = 0.049) in correlation to systemic 4-HPAA concentration.
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A likely candidate would have been MAO. As the pressor 
response is associated with the inhibition of MAO-A but not 
MAO-B (Finberg and Tenne, 1982; Finberg, 2014), only MAO-A 
should significantly influence systemic exposure to tyramine. 
There is extensive literature on the possible medical impact of 
inherited polymorphisms in MAO-A. Most of the more than 
500 publications on potential effects of MAO-A polymorphisms 
correlated polymorphisms in or near the MAO genes with 
complex neuropsychological or psychiatric phenotypes (Naoi 
et al., 2016). Literature data that links MAO-A polymorphisms 
to the enzyme’s expression or catalytic activity is scarce, and 
to the best of our knowledge, no in vivo metabolic phenotypes 
have been analysed in relation to MAO-A polymorphisms. 
Those polymorphisms were selected for investigation for which 
an association had been described, such as the 30-bp-VNTR 
localised 1.2 kb upstream of the MAO-A transcription starting 
site. Regarding this VNTR, Deckert and colleagues showed in 
luciferase reporter gene assays that the transcriptional activity 
was approximately 1.7-fold higher for the 3.5-repeat- compared 
to the 3-repeat-variant (Deckert et al., 1999). However, it was 
rare (< 3%) in the German population sample and was found 
in only one participant of our study (Supplementary Table 
1). The 4-repeat-variant was most abundant (61% prevalence 
in the German population sample) but was associated with 
merely 1.3-fold higher transcriptional activity compared to the 
3-repeats-variant. Another study also observed 1.3-fold and 
1.9-fold higher promoter activity for the 4-repeat- compared 
to the 3-repeat-allele in two different cell lines, while Sabol et 
al. found that the transcriptional efﬁciency was up to 4.6-fold 
and 4.8-fold higher in human cell lines carrying 3.5 or 4 repeats 
compared to those carrying 3 repeats (Sabol et al., 1998; Guo 
et al., 2008). For the single nucleotide polymorphism rs6323, 
a 3.8-fold higher mRNA expression and up to a 75% higher 
MAO-A activity was associated with the G-allele compared 
to the T-allele (Hotamisligil and Breakefield, 1991; Jansson 
et al., 2005; Leuchter et al., 2009; Zhang et al., 2010). With 
respect to rs1137070, a 2.3-fold higher mRNA expression was 
found in carriers of the T-allele in comparison to the C-allele, 
and for rs2072743, the mRNA expression was 3.8-fold higher 
with the A-allele compared to the G-allele (Zhang et al., 
2010). The frequent polymorphisms rs2064070 and rs909525 
were also included in our analysis. In addition, we were 
particularly interested in the functional effects of the MAO-A 
non-synonymous polymorphisms rs1800464 (R129W) and 
rs1799835 (V314F), but only one hemizygous male and three 
heterozygous female participants were carriers of the C-allele 
for rs1800464 and all participants had the same genotype with 
respect to rs1799835.
Despite some interesting indications from previous in vitro 
experiments, no effect was observed for any of these MAO-A 
polymorphisms on any relevant parameters reflecting tyramine 
pharmacokinetics or MOA-A-catalysed oxidative deamination 
resulting in 4-HPAA formation. It thus appears that genomic 
variation in MAO-A is not accountable for the variation in 
pharmacokinetics of tyramine. A possible explanation would be 
that the known genetic variants of MAO-A do not have a strong 
impact on the protein’s function in vivo, given the comparatively 
little (only up to 3-fold) variation in 4-HPAA plasma AUC and 
Ae0-6h (Figure 3). No bimodal or trimodal frequency distributions 
indicative of monogenetic polymorphisms were seen (Figure 3). 
One may conclude that genotypes predicting phenotypes with 
very low or very high MAO-A activity in humans are rare. For 
most of the polymorphisms studied here, the expected effect 
would have been a change in gene expression, which typically 
depends on a number of transcription factors. As gene regulation 
may be different in the central nervous system, the absence of a 
strong effect of these polymorphisms on peripheral MAO-A may 
not exclude an effect on transcription in the brain.
Despite the lack of influence for MAO-A genotypes on 
tyramine biotransformation, it is unlikely that MAO-A is of little 
relevance to the pharmacokinetics of tyramine. This is because 
76.8% of the applied tyramine dose was, on average, recovered in 
urine in form of 4-HPAA, the metabolite formed by MAO. Thus, 
our study confirmed in humans that MAO catalyses the main 
pathway in tyramine biotransformation and that tyramine might 
serve as a useful probe drug for studying MAO activity in vivo.
CYP2D6 is, due to its highly polymorphic nature, responsible 
for the variability in response to numerous substances, including 
more than 10% of all drugs. As was shown here, in a study with 
six deficient metabolisers and seven low activity intermediate 
metabolisers (the latter typically having less than 25% of usual 
activity) on the one side and four ultra-rapid metabolisers 
on the other side (Supplementary Table 1), there was no 
effect of CYP2D6 activity on tyramine pharmacokinetics or 
pharmacodynamics. Thus, CYP2D6 is irrelevant for the effects of 
dietary tyramine. Several studies found an association between 
CYP2D6 genotype and personality or brain imaging phenotypes 
(Llerena et al., 1993; Stingl et al., 2013). The formation of 
dopamine from endogenous precursors might be one mechanism 
behind these associations, but the present study does not support 
this hypothesis.
As more than 99.9% of tyramine is protonated at typical 
physiological pH in the relevant body compartments, tyramine 
should not be able to readily diffuse across membranes. Thus, 
its pharmacokinetics likely depend on a transport protein. In 
many subjects, tyramine was quite rapidly absorbed into the 
human body and appeared in the blood already 10 min after 
ingestion (Figure 6). The food interaction described for tyramine 
(VanDenBerg et al., 2003) may simply be due to slower gastric 
emptying with food, or, alternatively, may indicate competitive 
inhibition at transport proteins in the intestinal mucosa. OCT1 is 
highly expressed in liver sinusoidal membranes and only poorly 
expressed in the intestine. OCT1 genotypes should therefore be 
relevant for the hepatic clearance of tyramine from the systemic 
circulation rather than for intestinal absorption. However, our 
data provides no indication for that. Since the relevant hepatic 
uptake transporter for tyramine does not appear to be OCT1, 
it remains to be determined which other transporters could 
be responsible. Most tyramine was indeed recovered in urine 
in form of its metabolite 4-HPAA and thus had apparently 
entered the enterocytes and the hepatocytes. Other transporters 
that may participate in the absorption of organic cations in the 
small intestine include PMAT (SLC29A4), OCT3 (SLC22A3), 
OCTN1 (SLC22A4), OCTN2 (SLC22A5), NET1 (SLC6A2), 
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DAT1 (SLC6A3), SERT (SLC6A4), CHT1 (SLC5A7), CTL1-5 
(SLC44A1-5), and THRT2 (SLC19A3) (Zhou et al., 2007; 
Koepsell, 2015). However, their expression in the intestine may 
be relatively low and/or polymorphisms that strongly affect their 
function are not frequently found.
Tyramine was administered orally to resemble dietary 
tyramine, but the administered dose was higher than typical 
tyramine intake through nutrition. For instance, the tyramine 
concentration was found to be below 50 mg/kg for many 
different types of cheese, but can reach up to 1,000 mg/kg in 
matured cheese (Gillman, 2018). Other fermented foods, such 
as sausages, marmite, soybean products, and fish sauce, can 
also contain several hundred mg/kg of tyramine. Most wines 
and beers have concentrations of less than 10 mg/l, but a few 
were found to contain up to 100 mg/l. Fresh food products 
contain lesser amounts of tyramine, especially with modern 
production techniques and adequate food hygiene (Gillman, 
2018). According to literature data, the pressor response occurs 
at oral tyramine doses in the fasting state of 200 mg upwards 
(VanDenBerg et al., 2003; Di Stefano et al., 2013; Gillman, 2018). 
Higher systemic tyramine concentrations (e.g. in combination 
with MAO-A inhibitors) would likely show stronger effects, but 
in light of the fact that, already in this study, increases in systolic 
blood pressure by up to 100 mmHg were observed in some 
participants, the risk for adverse effects would be too high. It 
remains to be clarified why high blood pressure peaks were only 
found in some individuals, whereas in 90% of the participants, 
increases in systolic blood pressure were less than 40 mmHg. 
Given the high concentration-effect relationship (Figure 6), this 
may not necessarily be a result of genomic variation but could be 
due to other effects, such as the speed of gastric emptying or the 
passage time through the small intestine.
To summarise, extensive interindividual differences in 
tyramine AUC and large variation in blood pressure effects that 
correlated strongly with plasma tyramine concentration were 
seen in 88 healthy volunteers following administration of 400 mg 
tyramine. Despite several types of evidence from in vitro data that 
inherited MAO-A, CYP2D6, or OCT1 polymorphisms could 
be the underlying reason for the variation, we did not observe 
such an association in vivo. The data on the urinary recovery of 
4-HPAA, generated via MAO-A-catalysed oxidation, did not 
indicate the existence of common deficient, very low, or ultra-
active MAO-A phenotypes in humans. This study confirms that 
the therapeutic significance of any experimental observation and 
its relevance for humans should be confirmed in clinical studies 
and cannot be inferred from in vitro data alone, no matter how 
well obtained.
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